Advertisement
U.S. Markets open in 1 hr 38 mins

Lipigon Pharmaceuticals AB (publ) (9RP.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0010-0.0002 (-16.67%)
As of 08:13AM CEST. Market open.
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
9,327
16,407
0
3,180
4,278
-
Operating Expense
29,759
28,779
37,742
44,371
12,102
-
Operating Income
-20,432
-12,372
-37,742
-41,191
-7,824
-
Net Non Operating Interest Income Expense
177
243
37
78
7
-
Pretax Income
-20,255
-12,128
-37,705
-41,113
-8,068
-
Tax Provision
0
0
0
0
0
-
Net Income Common Stockholders
-20,255
-12,128
-37,705
-41,113
-8,068
-
Diluted NI Available to Com Stockholders
-20,255
-12,128
-37,705
-41,113
-8,068
-
Basic EPS
0.04
-0.19
-2.12
-3.35
-0.64
-
Diluted EPS
0.04
-0.19
-2.12
-3.35
-0.64
-
Basic Average Shares
64,114
64,121
17,791
12,271
12,526
-
Diluted Average Shares
125,791
64,121
17,791
12,271
12,526
-
Total Operating Income as Reported
-20,432
-12,371
-37,742
-41,191
-7,824
-
Total Expenses
29,759
28,779
37,742
44,371
12,102
-
Net Income from Continuing & Discontinued Operation
-20,255
-12,128
-37,705
-41,113
-8,068
-
Normalized Income
-20,255
-12,128
-37,705
-41,113
-7,817
-
Interest Income
238
246
37
83
10
-
Interest Expense
61
3
0
5
3
-
Net Interest Income
177
243
37
78
7
-
EBIT
-20,194
-12,125
-37,705
-41,108
-8,065
-
EBITDA
-20,170
-12,101
-37,681
-41,085
-8,065
-
Reconciled Depreciation
24.2
24
24
23
0
-
Net Income from Continuing Operation Net Minority Interest
-20,255
-12,128
-37,705
-41,113
-8,068
-
Total Unusual Items Excluding Goodwill
-
-
-
0
-251
-52
Total Unusual Items
-
-
-
0
-251
-52
Normalized EBITDA
-20,170
-12,101
-37,681
-41,085
-7,814
-
Tax Rate for Calcs
0
0
0
0
0
-
Tax Effect of Unusual Items
0
0
0
0
0
-